{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.4","upperLimit":"66.3","value":"33.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Overall survival was calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Oral pomalidomide 4 mg on Days 1-21 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity","id":"OG000","title":"Pomalidomide"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat population included all participants enrolled into the study","reportingStatus":"POSTED","timeFrame":"From randomization through the follow-up phase; Maximum time on follow-up was 141.1 weeks.","title":"Kaplan-Meier Estimate for Overall Survival","type":"SECONDARY","unitOfMeasure":"weeks"}